You Can’t Treat What You Can’t See: Ophthalmic Microscope Proveo 8

In the most critical moments of ophthalmic surgery, you need to be able to rely on consistent, uncompromised images, because you can’t treat what you can’t see.

The Proveo 8 ophthalmic microscope goes beyond conventional visualization. Its exclusive optical technology provides you with both constant red reflex and a rich texture view, throughout entire anterior and posterior procedures.

Proveo 8 pushes the boundaries of visualization:

  • CoAx4 Illumination technology for enhanced view during all cataract surgery stages, including phacoemulsification
  • FusionOptics technology for better texture view in retina and cataract surgery

Contact DB Surgical for more information.

Republished from Leica Microsystems

Leica Microsystems Receives Award as Technology Leader

Wetzlar, Germany. The research and consulting company Frost & Sullivan has recognized Leica Microsystems’ newly acquired Optical Coherence Tomography (OCT) company Bioptigen of Morrisville, North Carolina, USA, as a technology leader and pioneer of the North American ophthalmic imaging industry. The Frost & Sullivan Award ceremony took place January 13, 2016 in San Diego, USA.

In their appraisal, Frost & Sullivan calls attention to the value represented in Bioptigen’s OCT solutions: “Frost & Sullivan recognizes the enormous value addition Bioptigen’s Envisu Spectral Domain (SD)-OCT platform brings to ophthalmic imaging.”

Particularly emphasized are the highly customizable imaging solutions for pre-clinical and clinical applications. Bioptigen is offering hand-held OCT imaging capabilities bringing OCT directly to the patient. Quick and sensitive real-time OCT imaging minimizes the challenges of comprehensive eye examinations with supine and non-compliant patients, such as infants and children. Bioptigen offers the world’s only hand-held OCT solution approved by the FDA for use as an aid in the diagnosis of physiological and pathologic conditions of the eye.

Markus Lusser, President of Leica Microsystems, expressed his pride at the award: “Leica Microsystems is honored that Bioptigen has been selected for the Frost & Sullivan Award. It is tangible proof of the Bioptigen team’s dedication to creativity, innovation, and the constant exploration of growth potential in the vision healthcare market.”

Bioptigen develops and manufactures innovative OCT systems and software and provides products for clinical as well as translational research applications globally. Bioptigen currently markets the Envisu OCT for pediatric ophthalmic imaging applications, and a family of OCT imaging products for vision science research. Notably, in December 2015, the company received FDA clearance for EnFocus, an innovative OCT ophthalmic imaging solution to upgrade surgical microscopes with intrasurgical OCT capabilities directly integrated in the light path of the microscope. Bioptigen was acquired by Leica Microsystems in 2015.



 

 


Contact DB Surgical for more information.

Republished from Leica Microsystems

 

Leica Microsystems Launches New Ophthalmic Microscope Platform at AAO in Las Vegas

Proveo8-Surgical-Microscope_05

LAS VEGAS and WETZLAR, Germany. Leica Microsystems launches the Proveo 8, the core of a new ophthalmic microscope platform for cataract and vitreoretinal surgeries at the American Academy of Ophthalmology (AAO) Annual Meeting 2015 in Las Vegas, USA.

“‘You can’t treat what you can’t see’, is how a key opinion leader described one of the core challenges facing ophthalmic surgeons today,” says Markus Lusser, President of Leica Microsystems. “This is why we’ve designed our new Proveo platform to deliver exactly what an ophthalmic surgeon needs in order to perform a broad spectrum of ophthalmic procedures with confidence and efficiency. The Proveo 8 accomplishes this by providing consistent, uncompromised red reflex and a crisp, texture-rich image, especially during the most critical moments of each procedure.”

To deliver these advantages, the Proveo 8 is equipped with breakthrough innovations such as FusionOptics and CoAx4 Illumination. FusionOptics is a Leica exclusive technology that combines 40% increased depth of field with high resolution, providing surgeons with a texture-rich image from the edges of a detached membrane to the periphery of the retina, without refocusing. Another Leica exclusive feature, CoAx4 Illumination, delivers light through four individual beam paths and allows for adjustment of the illumination diameter. This results in constant red reflex and high contrast visualization without compromise for main surgeon or the assistant.

“The red reflex of the Proveo 8 is world class, with vividly contrasting edge of the capsulorhexis, but where Proveo has the real edge is in the Phacoemulsification process. Throughout Phaco, the microscope provides optical visibility with contrast, color rendition and crispness better than any other microscope,” says Dr. Ike Ahmed, Head of Ophthalmology at Trillium Health Partners, Mississauga, Ontario, Canada. He also adds: “Proveo is effective in teaching. Its assistant scope presents a full stereo view with excellent contrast and red reflex. Instructors and young surgeons sharing the same field of view accelerates the teaching process.”

The Proveo has been designed to easily integrate innovative surgical technologies like IOL guidance systems for precise IOL positioning, intraoperative OCT to observe ocular tissue microstructures, or 3D “heads-up” surgery. The integrated, yet modular design also allows easy upgrade for additional flexibility. The Proveo therefore provides ophthalmologists with a single platform solution to meet their anterior and posterior imaging needs today and tomorrow.

The American Academy of Ophthalmology (AAO) Annual Meeting 2015 in Las Vegas, USA will take place November 14 to 17, 2015. “We are really excited to unveil our new Proveo platform at AAO,” Lusser says. “With Proveo we developed a future-proof platform that was based on the input of many clinicians worldwide and we can’t wait to deliver the result into the hands of many new customers and contribute to their goal of improving clinical care in the growing ophthalmic surgery market.”

For more information about the Proveo 8 please check http://www.leica-microsystems.com/products/surgical-microscopes/ophthalmology/details/product/leica-proveo-8/

About Leica Microsystems

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. Ever since the company started as a family business in the nineteenth century, its instruments have been widely recognized for their optical precision and innovative technology. It is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopes.

Leica Microsystems has seven major plants and product development sites around the world. The company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Its headquarters are located in Wetzlar, Germany.

SOURCE Leica Microsystems